Estimating age-sex-race/ethnicity specific ASCVD death rates by the treatment eligible groups
4. These age-sex-race/ethnicity specific ASCVD death rates were the weighted average among individuals who were currently taking a statin and those who were not. We obtained the age-and race/ethnicity specific ASCVD death rates for non-statin users using DDij = (Dij / Nij) / ([Pij * 0.83 + (1 -Pij)])
where DDij = the age-and race/ethnicity specific ASCVD death rates among non-statin users for statin treatment eligibility groups i, Pij = the age-and race/ethnicity specific prevalence of current statin use for each treatment group, and 0.83 is the RR of ASCVD mortality comparing statin users with non-users for primary prevention. 5 To estimate DDij, we have approximated the observed RR by the causal RR estimates from the RCTs. We estimated age-specific prevalence by statin treatment eligibility groups and the reference group using NHANES 2005-2010. We included participants with ASCVD at baseline (n = 518) for prevalence estimate. Age-sex-race/ethnicity specific populations and the eligible population by statin treatment groups were obtained by multiplying the age-specific prevalence of non-statin users in each statin treatment eligibility group by the total number of the noninstitutionalized population derived from the Current Population Surveys (CPS). We used the midpoint CPS population of each survey cycle, and combined them as follows: 1/3 (NHANES 2005 (NHANES -2006 
CDC Wonder
We used CDC Wonder to estimate the annual age-sex-race/ethnicity specific number of ASCVD deaths, and calculated annual ASCVD death rates for those aged 40-75 years in 2010. We used 2010 US Census data as denominators for the annual ASCVD death rates (https://wonder.cdc.gov/ucd-icd10.html).
NHANES III Linked Mortality Files (1988-2006)
We used the NHANES III Linked Mortality Files (1988 Files ( -2006 to estimate the adjusted RRs comparing participants in treatment eligible group 1 (with diabetes), in treatment eligible group 2 (without diabetes but with an estimated 10-year risk of ASCVD ≥7.5%), with ASCVD at baseline with the participants with an estimated 10-year risk of ASCVD <7.5% (reference group) among participants 40-75 years of age by sex. These adjusted RRs were used to estimate age-sex-race/ethnicity specific ASCVD mortality by statin treatment eligibility groups for primary prevention of ASCVD.
Age-sexrace/ethnicity specific ASCVD mortality by statin treatment eligibility groups
We estimated age-sex-race/ethnicity specific ASCVD death rates by statin treatment eligibility group 1 and 2 (i.e., with diabetes (group 1) and without diabetes but with an estimated 10-year ASCVD risk ≥7.5% (group 2)) using age-sex-race/ethnicity specific population information, age-sex-race/ethnicity specific ASCVD deaths (derived from CDC Wonder), RRs of ASCVD associated with diabetes and with an estimated 10-year ASCVD risk ≥7.5% (derived from NHANES III Linked Mortality Files 1988-2006), age-sex-race/ethnicity specific prevalence of current statin use.
Population impact measures

Annual number of ASCVD deaths prevented
The age-and race/ethnicity specific number of annual ASCVD deaths prevented by statin treatment eligibility groups by sex:
where POPij=age-race/ethnicity specific eligible population (non-current statin users); DDij=treatment group-specific ASCVD death rates, i=1 to 4 groups, and j=1 to 16 age and race/ethnicity groups; Pi=proportion of population eligible for statin treatment complied with the statin therapy in treatment group i (assuming 100% statin use in primary analysis); RR =0.83 (95% CI, 0.72-0.96), estimated RR of statin use on ASCVD mortality.
Annual number of additional cases of diabetes
Annual number of additional cases of diabetes = ∑(excess incidence of diabetes associated with statin use * eligible population). The excess incidence of diabetes is estimated to be 1 per 1000 patients per year. 9 We assumed that those who died within 1 year contributed 0.5 person year.
Annual number of additional myopathy cases
Number of additional cases of myopathy = ∑(excess incidence of myopathy associated with statin use * eligible population). We estimated 2 sets of the annual number of excess myopathy cases by using results from a meta-analysis of RCTs and a population-based cohort study with more than 2 million patients in the QResearch database 7 8 For the RCTbased estimate, the excess incidence of myopathy or rhabdomyolysis was 0.0628 (95% CI, 0.167-0.292) per 1000 patient-years.
8 For the population-based estimate, myopathy included diagnosed myopathy or rhabdomyolysis or a raised upper limit of normal creatine kinase concentration ≥4, as the presence of these conditions likely resulted in treatment discontinuation.
7 For treatment group 1, the excess incidence of myopathy was 2.176 (95% CI, 1.769-2.655) and 0.791 (95% CI, 0.545-1.100) per 1000 patient-years for men and women, respectively. For treatment group 2, the corresponding numbers were 1.864 (95% CI, 1.515-2.282) and 0.632 (95% CI, 0.436-0.880), respectively.
Abbreviations: ASCVD, atherosclerosis cardiovascular diseases; CDC, Centers for Disease Control and Prevention; NHANES, National Health and Nutritional Examination Surveys; RR, relative risk.
* ASCVD includes ischemic heart diseases (ICD-10 I20-I25); cerebrovascular diseases excluding hemorrhagic cerebrovascular disease (ICD-10 I63-I69); atherosclerosis (ICD-10 I70) and other peripheral artery diseases (ICD-10 I73.9). 
